AbbVie Calls Retailers' Bystolic Generic Delay Claims Flawed

By Christopher Cole (September 21, 2021, 6:51 PM EDT) -- AbbVie has urged a New York federal judge to toss complaints from retailers CVS and Walgreens accusing the drugmaker of plotting to keep generic forms of the blockbuster drug Bystolic off the market.

AbbVie and other pharmaceutical companies targeted by the antitrust litigation said Monday that the direct buyer retailers cannot show that payments the defendants made to each other amid patent settlement deals come anywhere near the "large" and "unexplained" payments that would raise antitrust concerns under the U.S. Supreme Court's Actavis decision.

That 2013 ruling found that certain large payments to settle patent disputes amount to so-called "reverse payments"...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!